Immunovia continues with next stage of the Lung Cancer Project together with Global Pharma Partner
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today announced that the company’s Lung Cancer collaboration with a global pharmaceutical partner now enters the next stage of the study. The decision to advance was based on the solid progress of the previous study (link to press release).
In this stage of development, Immunovia will receive fresh blood samples from the pharma partner before the end of 2019 to begin the testing and analysis. The study will be finished in Q2 2020.
The main objective of the collaboration is to generate evidence of IMMray™ platforms performance in predicting response to drug treatments, which would facilitate selection of the right drug for the right patient.
Lung cancer is by far the leading cause of cancer death among both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. About 13% of all new cancers are lung cancers.
This expanded study will also benefit Immunovia’s early detection program, as well as provide an additional data set on the predictive performance capabilities of the IMMray™ platform.
For more information, please contact:
Director of Investor Relations
Tel: +46 7 93 486 277
This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CET on November 29, 2019.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.